A randomised phase II screening trial with functional imaging and patient reported toxicity sub-studies comparing Lapatinib plus capecitabine versus continued Trastuzumab plus capecitabine after local therapy in patients with ErbB2-positive metastatic breast cancer developing brain metastasis/es.

Trial Profile

A randomised phase II screening trial with functional imaging and patient reported toxicity sub-studies comparing Lapatinib plus capecitabine versus continued Trastuzumab plus capecitabine after local therapy in patients with ErbB2-positive metastatic breast cancer developing brain metastasis/es.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2015

At a glance

  • Drugs Lapatinib (Primary) ; Capecitabine; Trastuzumab
  • Indications Advanced breast cancer; Brain metastases
  • Focus Therapeutic Use
  • Acronyms LANTERN
  • Most Recent Events

    • 29 Oct 2013 Accrual to date is 25% according to United Kingdom Clinical Research Network record.
    • 17 Aug 2013 Accrual to date is 23% according to United Kingdom Clinical Research Network record.
    • 12 Jul 2013 Accrual to date is 21% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top